These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

170 related articles for article (PubMed ID: 36191144)

  • 1. Multivalent Display of ApoAI Peptides on the Surface of Tobacco Mosaic Virus Nanotubes Improves Cholesterol Efflux.
    Shin MD; Ortega-Rivera OA; Steinmetz NF
    Bioconjug Chem; 2022 Oct; 33(10):1922-1933. PubMed ID: 36191144
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Pegylation of high-density lipoprotein decreases plasma clearance and enhances antiatherogenic activity.
    Murphy AJ; Funt S; Gorman D; Tall AR; Wang N
    Circ Res; 2013 Jun; 113(1):e1-e9. PubMed ID: 23613182
    [TBL] [Abstract][Full Text] [Related]  

  • 3. ABCA1 Overexpression in Endothelial Cells In Vitro Enhances ApoAI-Mediated Cholesterol Efflux and Decreases Inflammation.
    Stamatikos A; Dronadula N; Ng P; Palmer D; Knight E; Wacker BK; Tang C; Kim F; Dichek DA
    Hum Gene Ther; 2019 Feb; 30(2):236-248. PubMed ID: 30079772
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Increased cholesterol efflux in apolipoprotein AI (ApoAI)-producing macrophages as a mechanism for reduced atherosclerosis in ApoAI((-/-)) mice.
    Major AS; Dove DE; Ishiguro H; Su YR; Brown AM; Liu L; Carter KJ; Linton MF; Fazio S
    Arterioscler Thromb Vasc Biol; 2001 Nov; 21(11):1790-5. PubMed ID: 11701467
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Inhibition of miR-33a-5p in Macrophage-like Cells In Vitro Promotes apoAI-Mediated Cholesterol Efflux.
    Oladosu O; Chin E; Barksdale C; Powell RR; Bruce T; Stamatikos A
    Pathophysiology; 2024 Feb; 31(1):117-126. PubMed ID: 38535619
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A pathway-dependent on apoE, ApoAI, and ABCA1 determines formation of buoyant high-density lipoprotein by macrophage foam cells.
    Yancey PG; Yu H; Linton MF; Fazio S
    Arterioscler Thromb Vasc Biol; 2007 May; 27(5):1123-31. PubMed ID: 17303773
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Inhibition of ERK1/2 and activation of liver X receptor synergistically induce macrophage ABCA1 expression and cholesterol efflux.
    Zhou X; Yin Z; Guo X; Hajjar DP; Han J
    J Biol Chem; 2010 Feb; 285(9):6316-26. PubMed ID: 20037141
    [TBL] [Abstract][Full Text] [Related]  

  • 8. ABCA1 and nascent HDL biogenesis.
    Wang S; Smith JD
    Biofactors; 2014; 40(6):547-54. PubMed ID: 25359426
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Featured Article: Delivery of chemotherapeutic vcMMAE using tobacco mosaic virus nanoparticles.
    Kernan DL; Wen AM; Pitek AS; Steinmetz NF
    Exp Biol Med (Maywood); 2017 Aug; 242(14):1405-1411. PubMed ID: 28675044
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Apolipoprotein AI and high-density lipoprotein have anti-inflammatory effects on adipocytes via cholesterol transporters: ATP-binding cassette A-1, ATP-binding cassette G-1, and scavenger receptor B-1.
    Umemoto T; Han CY; Mitra P; Averill MM; Tang C; Goodspeed L; Omer M; Subramanian S; Wang S; Den Hartigh LJ; Wei H; Kim EJ; Kim J; O'Brien KD; Chait A
    Circ Res; 2013 May; 112(10):1345-54. PubMed ID: 23501697
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Apolipoprotein AI efficiently binds to and mediates cholesterol and phospholipid efflux from human but not rat aortic smooth muscle cells.
    Francis GA; Tsujita M; Terry TL
    Biochemistry; 1999 Dec; 38(49):16315-22. PubMed ID: 10587456
    [TBL] [Abstract][Full Text] [Related]  

  • 12. ABCA1 mediates unfolding of apolipoprotein AI N terminus on the cell surface before lipidation and release of nascent high-density lipoprotein.
    Wang S; Gulshan K; Brubaker G; Hazen SL; Smith JD
    Arterioscler Thromb Vasc Biol; 2013 Jun; 33(6):1197-205. PubMed ID: 23559627
    [TBL] [Abstract][Full Text] [Related]  

  • 13. HDL Function and Atherosclerosis: Reactive Dicarbonyls as Promising Targets of Therapy.
    Linton MF; Yancey PG; Tao H; Davies SS
    Circ Res; 2023 May; 132(11):1521-1545. PubMed ID: 37228232
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Factors controlling nascent high-density lipoprotein particle heterogeneity: ATP-binding cassette transporter A1 activity and cell lipid and apolipoprotein AI availability.
    Lyssenko NN; Nickel M; Tang C; Phillips MC
    FASEB J; 2013 Jul; 27(7):2880-92. PubMed ID: 23543682
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Cholesterol efflux to apolipoprotein AI involves endocytosis and resecretion in a calcium-dependent pathway.
    Takahashi Y; Smith JD
    Proc Natl Acad Sci U S A; 1999 Sep; 96(20):11358-63. PubMed ID: 10500181
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Exosome-Mediated Transfer of Anti-miR-33a-5p from Transduced Endothelial Cells Enhances Macrophage and Vascular Smooth Muscle Cell Cholesterol Efflux.
    Stamatikos A; Knight E; Vojtech L; Bi L; Wacker BK; Tang C; Dichek DA
    Hum Gene Ther; 2020 Feb; 31(3-4):219-232. PubMed ID: 31842627
    [TBL] [Abstract][Full Text] [Related]  

  • 17. HDL particle size is a critical determinant of ABCA1-mediated macrophage cellular cholesterol export.
    Du XM; Kim MJ; Hou L; Le Goff W; Chapman MJ; Van Eck M; Curtiss LK; Burnett JR; Cartland SP; Quinn CM; Kockx M; Kontush A; Rye KA; Kritharides L; Jessup W
    Circ Res; 2015 Mar; 116(7):1133-42. PubMed ID: 25589556
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Macrophage apoAI protects against dyslipidemia-induced dermatitis and atherosclerosis without affecting HDL.
    Tavori H; Su YR; Yancey PG; Giunzioni I; Wilhelm AJ; Blakemore JL; Zabalawi M; Linton MF; Sorci-Thomas MG; Fazio S
    J Lipid Res; 2015 Mar; 56(3):635-643. PubMed ID: 25593328
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Humans with atherosclerosis have impaired ABCA1 cholesterol efflux and enhanced high-density lipoprotein oxidation by myeloperoxidase.
    Shao B; Tang C; Sinha A; Mayer PS; Davenport GD; Brot N; Oda MN; Zhao XQ; Heinecke JW
    Circ Res; 2014 May; 114(11):1733-42. PubMed ID: 24647144
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Dose-dependent action of atorvastatin in type IIB hyperlipidemia: preferential and progressive reduction of atherogenic apoB-containing lipoprotein subclasses (VLDL-2, IDL, small dense LDL) and stimulation of cellular cholesterol efflux.
    Guerin M; Egger P; Soudant C; Le Goff W; van Tol A; Dupuis R; Chapman MJ
    Atherosclerosis; 2002 Aug; 163(2):287-96. PubMed ID: 12052475
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.